Law360, New York ( August 25, 2014, 9:58 AM EDT) -- Many in the patent community, particularly in the pharmaceutical industry, were surprised when the Federal Circuit issued its April opinion in Gilead Sciences Inc. v. Natco Pharma Ltd., No. 2013-1418 (Fed. Cir. Apr. 22, 2014). The decision vacated and remanded that of the district court and held that plaintiff Gilead's earlier-issued (but later-expiring) '483 patent could be invalidated for obviousness-type double-patenting in view of Gilead's later-issued (but earlier-expiring) '375 patent. Slip Op. at 2-3....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.